When Standard Therapies Fail: MDT + CEUS Enables High-Risk TILs Cell Therapy for Advanced Tongue Cancer

BEIJING — In this landmark case — the first volume of Arion's "Case Breakthrough Notes" (破局手记) series edited by Prof. Bai Li, Prof. Sun Min (UPMC), and Prof. Ma Zhiqiang — a 54-year-old patient with stage IV tongue base squamous cell carcinoma had exhausted chemotherapy and targeted therapy. PD-L1 negative, with multiple cervical lymph node metastases compressing the jugular vein, the patient faced a critical dilemma: TILs cell therapy was the only remaining option, but the tumor biopsy required was deemed extremely high-risk due to the tumor's fusion with major vessels and central necrosis.

The Challenge: A Tumor Nobody Wanted to Biopsy

The patient's tongue base tumor had fused with the carotid artery and internal jugular vein. Imaging revealed extensive central necrosis — a blind biopsy risked missing viable tumor tissue, catastrophic bleeding, or both. Standard protocols would have declared the patient ineligible for TILs, as the therapy requires high-quality tumor tissue for lymphocyte expansion.

Arion's model, however, does not accept "too risky" as a final answer. The hospital activated its real-time full-term MDT mechanism, assembling a task force across eight departments.

The Solution: CEUS-Guided Precision Biopsy

Eight departments — Head & Neck Cancer Center, Cell Therapy Center, Diagnostic Radiology, Ultrasound, Nuclear Medicine, Pathology, Anesthesiology, and ICU — formed a multidisciplinary task force. The breakthrough came when the radiology and ultrasound team proposed contrast-enhanced ultrasound (CEUS)-guided core needle biopsy under local anesthesia.

CEUS precisely distinguished the tumor's active proliferative zone from necrotic areas and major vessels in real time. By injecting microbubble contrast agents and tracking perfusion patterns, the team mapped the tumor's "live" regions — areas with active blood supply and viable cancer cells — while clearly delineating the carotid artery, jugular vein, and necrotic core. This live vascular roadmap enabled the interventional radiologist to plan a safe needle trajectory that maximized tumor yield while completely avoiding vascular structures.

The 20-minute procedure successfully obtained 6 high-quality tissue cores with ≥60% tumor cell content — well above the threshold for TILs manufacturing — and zero complications. No bleeding. No vascular injury. Just clean, viable tumor tissue ready for the cell therapy pipeline.

From Tissue to Therapy: In-House GMP Manufacturing

The harvested tissue was immediately transferred under sterile cold-chain conditions to Arion's in-house GMP cell manufacturing workshop — a rare facility among Chinese private hospitals and a critical competitive advantage. Unlike most hospitals that must ship tissue to external CDMOs (contract development and manufacturing organizations), introducing cold-chain delays and viability losses, Arion's on-site GMP facility enabled same-day processing.

Over 35 days, the GMP team successfully isolated, activated, and expanded tumor-infiltrating lymphocytes (TILs) to clinically therapeutic doses. Quality control confirmed high viability (>90%), potent tumor reactivity, and sterility — meeting all release criteria for clinical infusion.

Treatment and Outcome

Following TILs manufacturing, the patient underwent a standardized treatment protocol:

1. Bridging chemotherapy — to control disease progression during the manufacturing window
2. Lymphodepletion — conditioning chemotherapy to create a favorable immune environment for TILs engraftment
3. TILs infusion — one-time intravenous infusion of the expanded autologous TILs
4. IL-2 support — low-dose interleukin-2 to support TILs expansion in vivo

At 1-month follow-up, the patient achieved stable disease with significant symptomatic relief. Dysphagia improved, neck pain resolved, and quality of life scores rose meaningfully. Long-term follow-up is ongoing.

"This case demonstrates a seamlessly integrated cell therapy platform — from software (MDT coordination across diagnosis, biopsy, manufacturing, and infusion) to hardware (on-site GMP facility minimizing cold-chain transit, maximizing cell viability). It's a replicable model for complex cancer treatment."

— Prof. Sun Min, UPMC Hillman Cancer Center

Key Takeaways

1. MDT collaboration turned a "too risky to biopsy" case into a safely executed TILs treatment. Eight departments working in real time transformed a clinical dead-end into a viable treatment path.
2. CEUS-guided biopsy is a replicable technical paradigm for complex tumor tissue acquisition. The combination of contrast-enhanced ultrasound with multidisciplinary planning can be applied to other anatomically challenging tumors.
3. Arion's on-site GMP cell manufacturing facility is a critical infrastructure advantage. In-house production eliminates cold-chain risks, reduces turnaround time, and maximizes cell viability — all essential for successful adoptive cell therapy.

About the Case Breakthrough Notes Series

"Case Breakthrough Notes" (破局手记) is Arion Cancer Hospital's flagship clinical case series, documenting complex cancer cases where multidisciplinary collaboration achieved breakthroughs beyond standard treatment protocols. The series is guided by:

• Prof. Bai Li — Honorary Editor-in-Chief, Senior Oncology Expert
• Prof. Sun Min — Honorary Editor-in-Chief, UPMC Hillman Cancer Center
• Prof. Ma Zhiqiang — Honorary Editor-in-Chief, Arion Cancer Hospital GI Oncology Center